Screener
Relay Therapeutics, Inc. RLAY Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Relay Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Relay Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338056
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accounts payable and accrued expenses | 24,188 | (4,399) |
| Deferred revenue | — | (7,679) |
| Other liabilities | 789 | (1,381) |
| Net cash used in operating activities | (105,221) | (128,471) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | — | (410) |
| Purchases of investments | (522,225) | (30,899) |
| Proceeds from maturities and sales of investments | 202,100 | 148,920 |
Item 1. Financial Statements.
FAQ
- What is Relay Therapeutics, Inc.'s operating cash flow?
- Relay Therapeutics, Inc. (RLAY) reported operating cash flow of -$54.11M in Q2 2026.
- How has Relay Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Relay Therapeutics, Inc.'s operating cash flow increased by 2.1% year-over-year, from -$55.26M to -$54.11M.
- What is the long-term trend for Relay Therapeutics, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s operating cash flow has grown at a 33.4% compound annual growth rate (CAGR), from -$74.41M to -$235.46M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Relay Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude